NAMS Menopause Certification Exam Prep Bundle | Complete
Questions, Answers & Rationales – Latest Update 2026/2027
Question 1
Which hormonal change is considered the earliest reliable endocrine
marker of the approaching menopausal transition?
• A. Significant rise in serum follicle-stimulating hormone (FSH)
• B. Marked decrease in anti-Müllerian hormone (AMH) levels
• C. Complete cessation of dehydroepiandrosterone sulfate (DHEA-
S)
• D. Acute drop in thyroid-stimulating hormone (TSH)
Correct Answer: B. Marked decrease in anti-Müllerian hormone (AMH)
levels
Detailed Rationale: AMH declines steadily as the ovarian follicle pool
diminishes, serving as an early indicator of reproductive aging before
FSH levels rise significantly.
Question 2
What is a critical long-term health rationale for maintaining hormone
therapy in young women diagnosed with premature ovarian
insufficiency (POI) until the natural age of menopause?
• A. Prevention of rapid bone mineral density loss and reduction of
cardiovascular risks associated with early estrogen deprivation
• B. Permanent prevention of all future gynecological malignancies
, • C. Enhancement of fertility potential past age 45
• D. Elimination of the need for routine lipid monitoring
Correct Answer: A. Prevention of rapid bone mineral density loss and
reduction of cardiovascular risks associated with early estrogen
deprivation
Detailed Rationale: Women with POI experience prolonged estrogen
deficiency, which significantly increases their lifetime risk of
osteoporosis and cardiovascular disease unless treated with hormone
therapy until natural menopausal age.
Question 3
When prescribing systemic menopausal hormone therapy (MHT) to a
woman with an intact uterus, why is the inclusion of a progestogen
component mandatory?
• A. To prevent endometrial hyperplasia and carcinoma induced by
unopposed estrogen stimulation
• B. To prevent systemic venous thromboembolism
• C. To maximize the absorption of the transdermal estrogen patch
• D. To stimulate hepatic synthesis of high-density lipoprotein (HDL)
Correct Answer: A. To prevent endometrial hyperplasia and carcinoma
induced by unopposed estrogen stimulation
Detailed Rationale: Unopposed estrogen uninhibitedly stimulates
endometrial tissue proliferation, substantially increasing the risk of
endometrial hyperplasia and cancer. Progestogen counteracts this effect
by inducing secretory changes and shedding.
,Question 4
Why does transdermal estradiol therapy carry a lower risk of venous
thromboembolism (VTE) compared to oral estrogen formulations?
• A. Transdermal administration bypasses hepatic first-pass
metabolism, avoiding up-regulation of clotting factors and
inflammatory markers.
• B. Transdermal patches contain intrinsic anticoagulant
medications.
• C. Oral estrogen tablets destroy platelets instantly.
• D. Transdermal estrogen lowers serum triglyceride concentrations
to zero.
Correct Answer: A. Transdermal administration bypasses hepatic first-
pass metabolism, avoiding up-regulation of clotting factors and
inflammatory markers.
Detailed Rationale: Oral estrogens pass directly through the liver via
the portal circulation, stimulating hepatic production of coagulation
factors and inflammatory proteins, whereas transdermal delivery avoids
this hepatic first-pass impact.
Question 5
Which mechanism explains how low-dose selective serotonin reuptake
inhibitors (SSRIs) reduce vasomotor symptoms?
• A. Modulating central thermoregulatory pathways and stabilizing
neurotransmitter tone in the hypothalamus
• B. Inducing selective vasoconstriction of peripheral skin arterioles
, • C. Blocking peripheral beta-2 adrenergic receptors
• D. Inhibiting the hepatic breakdown of endogenous estrogen
Correct Answer: A. Modulating central thermoregulatory pathways and
stabilizing neurotransmitter tone in the hypothalamus
Detailed Rationale: SSRIs and SNRIs increase serotonin and
norepinephrine availability in the central nervous system, which helps
reset and stabilize the narrowed thermoneutral zone within the
hypothalamic thermoregulatory center.
Question 6
What is a primary pharmacokinetic advantage of low-dose vaginal
estrogen preparations in treating genitourinary syndrome of
menopause (GSM)?
• A. They provide local relief while resulting in minimal systemic
absorption, generally avoiding the need for concurrent
progestogen in women with an intact uterus.
• B. They permanently restore ovarian follicle production.
• C. They are completely absorbed into the portal vein to alter lipid
metabolism.
• D. They eliminate all forms of lower urinary tract infections
permanently.
Correct Answer: A. They provide local relief while resulting in minimal
systemic absorption, generally avoiding the need for concurrent
progestogen in women with an intact uterus.
Questions, Answers & Rationales – Latest Update 2026/2027
Question 1
Which hormonal change is considered the earliest reliable endocrine
marker of the approaching menopausal transition?
• A. Significant rise in serum follicle-stimulating hormone (FSH)
• B. Marked decrease in anti-Müllerian hormone (AMH) levels
• C. Complete cessation of dehydroepiandrosterone sulfate (DHEA-
S)
• D. Acute drop in thyroid-stimulating hormone (TSH)
Correct Answer: B. Marked decrease in anti-Müllerian hormone (AMH)
levels
Detailed Rationale: AMH declines steadily as the ovarian follicle pool
diminishes, serving as an early indicator of reproductive aging before
FSH levels rise significantly.
Question 2
What is a critical long-term health rationale for maintaining hormone
therapy in young women diagnosed with premature ovarian
insufficiency (POI) until the natural age of menopause?
• A. Prevention of rapid bone mineral density loss and reduction of
cardiovascular risks associated with early estrogen deprivation
• B. Permanent prevention of all future gynecological malignancies
, • C. Enhancement of fertility potential past age 45
• D. Elimination of the need for routine lipid monitoring
Correct Answer: A. Prevention of rapid bone mineral density loss and
reduction of cardiovascular risks associated with early estrogen
deprivation
Detailed Rationale: Women with POI experience prolonged estrogen
deficiency, which significantly increases their lifetime risk of
osteoporosis and cardiovascular disease unless treated with hormone
therapy until natural menopausal age.
Question 3
When prescribing systemic menopausal hormone therapy (MHT) to a
woman with an intact uterus, why is the inclusion of a progestogen
component mandatory?
• A. To prevent endometrial hyperplasia and carcinoma induced by
unopposed estrogen stimulation
• B. To prevent systemic venous thromboembolism
• C. To maximize the absorption of the transdermal estrogen patch
• D. To stimulate hepatic synthesis of high-density lipoprotein (HDL)
Correct Answer: A. To prevent endometrial hyperplasia and carcinoma
induced by unopposed estrogen stimulation
Detailed Rationale: Unopposed estrogen uninhibitedly stimulates
endometrial tissue proliferation, substantially increasing the risk of
endometrial hyperplasia and cancer. Progestogen counteracts this effect
by inducing secretory changes and shedding.
,Question 4
Why does transdermal estradiol therapy carry a lower risk of venous
thromboembolism (VTE) compared to oral estrogen formulations?
• A. Transdermal administration bypasses hepatic first-pass
metabolism, avoiding up-regulation of clotting factors and
inflammatory markers.
• B. Transdermal patches contain intrinsic anticoagulant
medications.
• C. Oral estrogen tablets destroy platelets instantly.
• D. Transdermal estrogen lowers serum triglyceride concentrations
to zero.
Correct Answer: A. Transdermal administration bypasses hepatic first-
pass metabolism, avoiding up-regulation of clotting factors and
inflammatory markers.
Detailed Rationale: Oral estrogens pass directly through the liver via
the portal circulation, stimulating hepatic production of coagulation
factors and inflammatory proteins, whereas transdermal delivery avoids
this hepatic first-pass impact.
Question 5
Which mechanism explains how low-dose selective serotonin reuptake
inhibitors (SSRIs) reduce vasomotor symptoms?
• A. Modulating central thermoregulatory pathways and stabilizing
neurotransmitter tone in the hypothalamus
• B. Inducing selective vasoconstriction of peripheral skin arterioles
, • C. Blocking peripheral beta-2 adrenergic receptors
• D. Inhibiting the hepatic breakdown of endogenous estrogen
Correct Answer: A. Modulating central thermoregulatory pathways and
stabilizing neurotransmitter tone in the hypothalamus
Detailed Rationale: SSRIs and SNRIs increase serotonin and
norepinephrine availability in the central nervous system, which helps
reset and stabilize the narrowed thermoneutral zone within the
hypothalamic thermoregulatory center.
Question 6
What is a primary pharmacokinetic advantage of low-dose vaginal
estrogen preparations in treating genitourinary syndrome of
menopause (GSM)?
• A. They provide local relief while resulting in minimal systemic
absorption, generally avoiding the need for concurrent
progestogen in women with an intact uterus.
• B. They permanently restore ovarian follicle production.
• C. They are completely absorbed into the portal vein to alter lipid
metabolism.
• D. They eliminate all forms of lower urinary tract infections
permanently.
Correct Answer: A. They provide local relief while resulting in minimal
systemic absorption, generally avoiding the need for concurrent
progestogen in women with an intact uterus.
